Dr Reddys Laboratories (RDY) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $13.07, +1.32% vs the prior close of $12.90.
- Volume 2.79M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RDY rises 1.3% to $13.07, a 3-month high. Closed at $13.07, +1.32% vs the prior close of $12.90. Day range $12.94–$13.07, opened at $13.00.
RDY daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — RDY rises 1.3% to $13.07, a 3-month high
- Closed at $13.07, +1.32% vs the prior close of $12.90. Day range $12.94–$13.07, opened at $13.00.
- Volume was 2.79M shares, 1.0x its 50-day average of 2.84M.
- Price is +6.5% vs its 50-day average ($12.27) and -1.1% vs its 200-day average ($13.22).
- 52-week range $11.36–$15.67; today's close sits at 40% of that range, 16.6% below the 52-week high.
Oct 15, 2026 — RDY rises 1.2% to $12.90, a 3-month high
- Closed at $12.90, +1.18% vs the prior close of $12.75. Day range $12.84–$13.04, opened at $12.89.
- Volume was 2.75M shares, 1.0x its 50-day average of 2.84M.
- Price is +5.3% vs its 50-day average ($12.25) and -2.4% vs its 200-day average ($13.22).
- 52-week range $11.36–$15.67; today's close sits at 36% of that range, 17.7% below the 52-week high.
Oct 14, 2026 — RDY ends flat (-0.2%) to $12.75
- Closed at $12.75, -0.16% vs the prior close of $12.77. Day range $12.65–$12.94, opened at $12.70.
- Volume was 3.74M shares, 1.3x its 50-day average of 2.82M.
- Price is +4.2% vs its 50-day average ($12.24) and -3.6% vs its 200-day average ($13.23).
- 52-week range $11.36–$15.67; today's close sits at 32% of that range, 18.6% below the 52-week high.
- SEC filings that day: 6-K.
Oct 13, 2026 — RDY dips 0.4% to $12.77
- Closed at $12.77, -0.39% vs the prior close of $12.82. Day range $12.74–$12.95, opened at $12.92.
- Volume was 2.72M shares, 1.0x its 50-day average of 2.83M.
- Price is +4.5% vs its 50-day average ($12.22) and -3.5% vs its 200-day average ($13.23).
- 52-week range $11.36–$15.67; today's close sits at 33% of that range, 18.5% below the 52-week high.
Oct 12, 2026 — RDY rises 2.7% to $12.82
- Closed at $12.82, +2.72% vs the prior close of $12.48. Day range $12.60–$12.99, opened at $12.60.
- Volume was 2.16M shares, 0.8x its 50-day average of 2.85M.
- Price is +5.0% vs its 50-day average ($12.21) and -3.2% vs its 200-day average ($13.24).
- 52-week range $11.36–$15.67; today's close sits at 34% of that range, 18.2% below the 52-week high.
Oct 9, 2026 — RDY rises 2.3% to $12.48
- Closed at $12.48, +2.30% vs the prior close of $12.20. Day range $12.33–$12.53, opened at $12.33.
- Volume was 1.97M shares, 0.7x its 50-day average of 2.85M.
- Price is +2.4% vs its 50-day average ($12.19) and -5.8% vs its 200-day average ($13.25).
- 52-week range $11.36–$15.67; today's close sits at 26% of that range, 20.4% below the 52-week high.
Oct 8, 2026 — RDY dips 0.6% to $12.20
- Closed at $12.20, -0.57% vs the prior close of $12.27. Day range $11.99–$12.29, opened at $12.07.
- Volume was 3.83M shares, 1.4x its 50-day average of 2.82M.
- Price is +0.2% vs its 50-day average ($12.18) and -8.0% vs its 200-day average ($13.26).
- 52-week range $11.36–$15.67; today's close sits at 19% of that range, 22.1% below the 52-week high.
- SEC filings that day: 6-K.
Oct 7, 2026 — RDY dips 1.8% to $12.27
- Closed at $12.27, -1.76% vs the prior close of $12.49. Day range $12.22–$12.40, opened at $12.40.
- Volume was 3.12M shares, 1.1x its 50-day average of 2.84M.
- Price is +0.8% vs its 50-day average ($12.17) and -7.5% vs its 200-day average ($13.27).
- 52-week range $11.36–$15.67; today's close sits at 21% of that range, 21.7% below the 52-week high.
- SEC filings that day: 6-K.
Oct 6, 2026 — RDY rises 1.4% to $12.49
- Closed at $12.49, +1.38% vs the prior close of $12.32. Day range $12.31–$12.56, opened at $12.38.
- Volume was 4.00M shares, 1.4x its 50-day average of 2.84M.
- Price is +2.7% vs its 50-day average ($12.16) and -5.9% vs its 200-day average ($13.27).
- 52-week range $11.36–$15.67; today's close sits at 26% of that range, 20.3% below the 52-week high.
Oct 5, 2026 — RDY rises 0.6% to $12.32
- Closed at $12.32, +0.57% vs the prior close of $12.25. Day range $12.16–$12.34, opened at $12.25.
- Volume was 2.74M shares, 1.0x its 50-day average of 2.85M.
- Price is +1.5% vs its 50-day average ($12.14) and -7.2% vs its 200-day average ($13.28).
- 52-week range $11.36–$15.67; today's close sits at 22% of that range, 21.4% below the 52-week high.
- SEC filings that day: 6-K.
Oct 2, 2026 — RDY ends flat (+0.0%) to $12.25, 3 down days in a row
- Closed at $12.25, +0.00% vs the prior close of $12.25. Day range $12.08–$12.31, opened at $12.29.
- Volume was 3.80M shares, 1.3x its 50-day average of 2.92M.
- Price is +1.0% vs its 50-day average ($12.13) and -7.8% vs its 200-day average ($13.29).
- 52-week range $11.36–$15.67; today's close sits at 21% of that range, 21.8% below the 52-week high.
- That makes 3 straight losses.
RDY latest news & SEC filings
Every SEC filing by or about RDY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 8, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 7, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 5, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 22, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 21, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 18, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 14, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 10, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 10, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 26, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 17, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 17, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 13, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 10, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade RDY
- How much it moves: over the last 20 sessions the average daily move was 1.38% (largest 2.9%).
- Liquidity: about 3.19M shares (≈$41.66M) trade per day on average.
- 52-week position: $13.07 vs a range of $11.36–$15.67 (40% of the range).
- Dividends: last ex-dividend date Jul 24, 2026 ($0.083/share); 1 payments in the past 12 months.
- Splits: 5:1 on Nov 5, 2024
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 6-K Oct 14, 2026; 6-K Oct 8, 2026; 6-K Oct 7, 2026.
- Listing: NYSE · industry: Pharmaceutical Preparations.
RDY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 13.00 | 13.07 | 12.94 | 13.07 | 2.79M |
| Oct 15, 2026 | 12.89 | 13.04 | 12.84 | 12.90 | 2.75M |
| Oct 14, 2026 | 12.70 | 12.94 | 12.65 | 12.75 | 3.74M |
| Oct 13, 2026 | 12.92 | 12.95 | 12.74 | 12.77 | 2.72M |
| Oct 12, 2026 | 12.60 | 12.99 | 12.60 | 12.82 | 2.16M |
| Oct 9, 2026 | 12.33 | 12.53 | 12.33 | 12.48 | 1.97M |
| Oct 8, 2026 | 12.07 | 12.29 | 11.99 | 12.20 | 3.83M |
| Oct 7, 2026 | 12.40 | 12.40 | 12.22 | 12.27 | 3.12M |
| Oct 6, 2026 | 12.38 | 12.56 | 12.31 | 12.49 | 4.00M |
| Oct 5, 2026 | 12.25 | 12.34 | 12.16 | 12.32 | 2.74M |
| Oct 2, 2026 | 12.29 | 12.31 | 12.08 | 12.25 | 3.80M |
| Oct 1, 2026 | 12.38 | 12.55 | 12.24 | 12.25 | 3.17M |
| Sep 30, 2026 | 12.72 | 12.75 | 12.53 | 12.62 | 3.94M |
| Sep 29, 2026 | 12.91 | 12.99 | 12.74 | 12.85 | 4.80M |
| Sep 28, 2026 | 12.44 | 12.67 | 12.43 | 12.51 | 4.03M |
| Sep 25, 2026 | 12.31 | 12.35 | 12.17 | 12.25 | 3.17M |
| Sep 24, 2026 | 12.30 | 12.44 | 12.25 | 12.30 | 3.04M |
| Sep 23, 2026 | 12.52 | 12.58 | 12.36 | 12.39 | 2.49M |
| Sep 22, 2026 | 12.55 | 12.72 | 12.48 | 12.57 | 3.09M |
| Sep 21, 2026 | 12.37 | 12.46 | 12.25 | 12.40 | 2.39M |
About Dr Reddys Laboratories
Dr Reddys Laboratories (RDY) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in HYDERABAD. State of incorporation: India. Fiscal year ends March 31. SEC CIK 1135951.
RDY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Pranatharthi Haran Krishnan Kodumudi | Director | Mar 27, 2026 |
| Arun Madhavan Kumar | Director | Mar 27, 2026 |
| Sanjiv Soshil Mehta | Director | Mar 27, 2026 |
| Leo Puri | Director | Mar 27, 2026 |
| G V Prasad | Director | Mar 20, 2026 |
| K Satish Reddy | Director | Mar 20, 2026 |
| Shikha Sanjaya Sharma | Director | Mar 27, 2026 |
| Alpna Seth | Director | Apr 1, 2026 |
| Penny Chan Wan | Director | Mar 27, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Patrick Rudolf Aghanian | Head - Europe Generics | Apr 1, 2026 |
| Srinivasa Phanimitra Bhethanabottla | Chief Information Officer | Apr 1, 2026 |
| Erez Israeli | CHIEF EXECUTIVE OFFICER | Apr 1, 2026 |
| Milan Kantilal Kalawadia | CEO - North America | Apr 1, 2026 |
| Sushrut Kulkarni | GLOBAL HEAD - IPDO | Apr 1, 2026 |
| Venkata Narasimham Mannam | Chief Financial Officer | Apr 1, 2026 |
| Venkata Ramana Motupalli | CEO - Global Generics | Apr 1, 2026 |
| Madhu Sundar Subramanian Munnirpallam | Global Head of Quality and PV | Apr 10, 2026 |
| Deepak Sapra | CEO - API and Services | Apr 1, 2026 |
| Krishna Venkatesh | Global Head - IPDO | Apr 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
RDY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
RDY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on RDY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.